Unhealthy alcohol use (the spectrum of risky use through dependence) is common in HIV-infected persons, yet it can interfere with HIV medication adherence, may lower CD4 cell count, and can cause hepatic injury. Carbohydrate-deficient transferrin (CDT), often measured as %CDT, can detect heavy drinking but whether it does in people with HIV is not well established. We evaluated the operating characteristics of %CDT in HIVinfected adults using cross-sectional data from 300 HIV-infected adults with current or past alcohol problems. Past 30-day alcohol consumption was determined using the Timeline Followback (TLFB), a validated structured recall questionnaire, as the reference standard. Sensitivity and specificity of %CDT (at manufacturer's cut-off point of 2.6%) for detecting both ''at-risk'' (]4 drinks in a day or !7 drinks per week for women, ]5 drinks in a day or !14 per week for men) and ''heavy'' drinking (]4 drinks in a day for women, ]5 drinks in a day for men on at least seven days) were calculated. Receiver operating characteristic (ROC) curves were estimated to summarize the diagnostic ability of %CDT for distinguishing ''at risk'' and ''heavy'' levels of drinking. Exploratory analyses that stratified by gender and viral hepatitis infection were performed. Of 300 subjects, 103 reported current consumption at ''at-risk'' amounts, and 47 reported ''heavy'' amounts. For ''at-risk'' drinking, sensitivity of %CDT was 28% (95% confidence interval (CI) 19%, 37%), specificity 90% (95% CI 86%, 94%); area under the ROC curve (AUC) was 0.59. For ''heavy'' drinking, sensitivity was 36% (95% CI 22%, 50%), specificity 88% (95% CI 84%, 92%); AUC was 0.60. Sensitivity appeared lower among women and those with viral hepatitis; specificity was similar across subgroups. Among HIV-infected adults, %CDT testing yielded good specificity, but poor sensitivity for detecting ''at-risk'' and ''heavy'' alcohol consumption, limiting its clinical utility for detecting unhealthy alcohol use in this population.
Background
HIV-infected populations in the USA have a high prevalence of unhealthy alcohol use, which can contribute to declines in their health (Cook et al., 2001; Galvan et al., 2002; Saitz, 2005; Samet, Phillips, Horton, Traphagen, & Freedberg, 2004) . Alcohol can adversely affect immune function (Greiffenstein & Molina, 2008; Watzl & Watson, 1992) , nutritional status (Lieber, 2003; Martin Villares et al., 2004) and adherence to medications (Braithwaite et al., 2005; Heckman, Catz, Heckman, Miller, & Kalichman, 2004) . It can interfere with hepatic metabolism and is hepatotoxic. Furthermore, HIV co-infection with viral hepatitis is common (Shire et al., 2007; Tedaldi et al., 2003) , and both HIV and viral hepatitis are adversely impacted by alcohol. For these reasons, detection of unhealthy alcohol use is important in the clinical care of HIV-infected individuals.
There is evidence that early intervention for unhealthy alcohol use can be effective (Kaner et al., 2009; Nilssen, 2004) , but early clinical signs are often missed (Weisner & Matzger, 2003) and unhealthy alcohol use often goes undiagnosed by HIV healthcare providers (Conigliaro et al., 2003) . The National Institute on Alcohol Abuse and Alcoholism (NIAAA) advises screening for unhealthy alcohol use (National Institute on Alcohol Abuse and Alcoholism, 2007) by assessing for ''at-risk'' drinking amounts. These are drinking amounts that put individuals at increased risk of adverse health *Corresponding author. Email: Julia.Ireland@fenwayhealth.org AIDS Care Vol. 23, No. 11, November 2011 effects including alcohol use disorders (abuse and dependence).
Practice guidelines recommend screening by using questionnaires. Biomarkers are not standard for universal alcohol screening because they are more costly and less sensitive for unhealthy use than questionnaires (Coulton et al., 2006) . But some have recommended their use. Biomarkers can be useful for detecting unhealthy use among those who deny it, helping to confirm unhealthy use, or to facilitate discussions with patients about alcohol by having a seemingly more objective medical test in hand (Miller & Anton, 2004) . Biomarkers are sometimes used for monitoring of heavy alcohol use (Anton, Lieber, Tabakoff, & CDTect Study Group, 2002) .
A number of biomarkers are affected by unhealthy alcohol consumption, e.g., lipids and liver enzymes, but none has both sufficient sensitivity and specificity for screening. The most common biomarkers currently used for detection of unhealthy alcohol use include the liver enzyme g-glutamyltransferase (GGT), which is neither particularly sensitive nor specific for detecting unhealthy alcohol use (Conigrave et al., 2002; Schmidt et al., 1997; Schwan et al., 2004) . Other biomarkers are red blood cell mean corpuscular volume (MCV), and a protein produced by the liver, carbohydrate-deficient transferrin (CDT), often measured as %CDT. Of these, only CDT has high specificity for unhealthy alcohol use (Schwan et al., 2004) , does not remain elevated as long after an episode of unhealthy drinking as GGT (Schmidt et al., 1997) , and retains specificity when liver disease is present (e.g., primary biliary cirrhosis) (Arndt, Meier, Nauck, & Gressner, 2006) .
CDT's performance for detecting unhealthy alcohol use in people with HIV has not been wellestablished. HIV-infected populations have a high prevalence of abnormal liver enzymes. CDT might therefore be more sensitive and less specific for unhealthy alcohol consumption than it is in populations without HIV infection or with undetermined HIV status.
CDT operates in a dose-dependent manner as a biomarker for detecting alcohol consumption (Schellenberg et al., 2005) . If CDT were able to detect ''at-risk'' drinking (the spectrum of ''at-risk'' use through dependence) in HIV-infected individuals, it could be very useful clinically (Conigliaro et al., 2003) . Therefore, our primary objective was to evaluate the diagnostic accuracy of CDT to distinguish between ''at-risk'' and lesser than ''atrisk'' drinking in adults with HIV infection.
Methods

Subjects
We studied cross-sectional data collected prospectively for an observational cohort study, the HIV-Longitudinal Interrelationships of Viruses and Ethanol (HIV-LIVE) study (Samet et al., 2007) . Subjects (n 0400) were recruited from 2001 to 2003 in the Boston area mainly from clinical settings (Samet et al., 2007) . Mean age was 43, 75% were male, 33% white, 41% black, 19% Hispanic, approximately two-thirds were ''heterosexual,'' one-third ''gay or homosexual,'' and 56% had a lifetime history of injection drug use.
All subjects met the following eligibility criteria: (1) current or past alcohol problems (]two affirmative responses to the CAGE alcohol screening questionnaire or diagnosis of alcohol abuse or dependence based on clinical assessment by a physicianinvestigator); (2) HIV infection documented by an ELISA antibody test confirmed by western blot; (3) ability to speak English or Spanish; and (4) at least one contact person to assist with follow-up. Eligible subjects provided written informed consent before enrollment.
Exclusion criteria for the HIV-LIVE study were score of B21 on the Mini-Mental State Exam or trained-interviewer assessment of individual's inability to comprehend informed consent or answer interview questions. Additional exclusion criteria were lack of baseline hepatitis C RNA (viral load) data, missing responses to the TLFB questions, insufficient blood sample quantity, and inability to match blood sample to same-day questionnaire data.
Assessments
Laboratory tests and interviews by trained research associates were done at baseline and every six months for at least 24 months and up to 42 months ending in 2006. Blood samples were collected for storage annually. The Federal Government provided a certificate of confidentiality for added protection for the research data. The study was approved by the Institutional Review Boards at Boston Medical Center and Beth Israel Deaconess Hospital.
The reference standard used for determining past 30-day alcohol consumption was the TLFB, a lengthy validated structured recall questionnaire for assessing alcohol consumption over time in research studies (Carey, Carey, Maisto, & Henson, 2004; Sacks, Drake, Williams, Banks, & Herrell, 2003; Sobell & Sobell, 1995) . We evaluated the ability of %CDT and GGT to detect three levels of unhealthy alcohol consumption: ''at-risk,'' ''heavy,'' and ''frequent heavy'' drinking as determined by the reference standard TLFB.
We used the NIAAA definition of ''at-risk'' drinking (National Institute on Alcohol Abuse and Alcoholism, 2007), but placed it in the context of a 30-day period: ]4 drinks in a day in past 30 days or !7 drinks per week on average for women; ]5 drinks in a day in past 30 days or !14 drinks per week on average for men. We defined ''heavy'' drinking as at least seven days of drinking at ]4 drinks in a day for women and ]5 drinks in a day for men in past 30 days, amounts at which physiologic and/or organ damage become more likely (Conigrave et al., 2002; White, Altmann, & Nanchahal, 2002) . We defined ''frequent heavy'' drinking as at least seven consecutive days of ''heavy'' drinking in past 30 days. We used the NIAAA definition of one drink: 12 ounces beer, 5 ounces of wine or 1.5 ounces of 80 proof liquor (containing approximately 14 grams or 0.6 fluid ounces of pure alcohol) (National Institute on Alcohol Abuse and Alcoholism, 2007) .
Data collection at study entry included the following: age, gender, current viral hepatitis B and C infection (hepatitis B infection determined by the presence of surface antigen; hepatitis C infection determined by the presence of hepatitis C RNA). Follow-up interviews were conducted every six months and generally replicated the baseline interview content.
Sample selection and testing
This study allowed for the testing of 300 blood specimens for %CDT. To ensure adequate sample sizes for the estimation of sensitivity and specificity of %CDT for distinguishing between ''at-risk'' drinking and lesser than ''at-risk'' drinking, we sought to have the sample consist of approximately equal numbers of ''at-risk'' and lesser than ''at-risk'' drinkers. Sensitivity is the proportion of people who meet criteria for unhealthy alcohol use and who have a positive test result. Specificity is the proportion of people who do not meet the criteria who have a negative test result. Thus, all 103 HIV-LIVE subjects reporting ''at-risk'' drinking were included in the sample of 300, including 47 who reported ''heavy'' drinking amounts, 22 of whom also reported ''frequent heavy'' drinking.
All 67 HIV-LIVE subjects who reported consumption that was lesser than ''at-risk'' but not abstinent (no drinking in past 30 days) were included in the study sample. All of these were included in an attempt to have similar numbers with lower risk drinking as with abstinence. To complete the sample of 300 unique subjects, 130 were randomly selected from the remaining subjects, all of whom who reported abstinence. Subjects with multiple samples had a single sample randomly selected.
Selected blood samples were sent for %CDT and GGT analysis to a single laboratory, the Clinical Neurobiological Laboratory at the Medical University of South Carolina. CDT was measured as %CDT using the most recent iteration of the Axis-Shield turbidimetric immunoassay, %CDT-TIA, using the manufacturer's recommended cut-off point of 2.6% to define a positive test. GGT positive cut-off points were defined as ]30U/L for women and ]40U/L for men.
Analysis
All analyses were performed using SAS version 9.1.3 (Cary, NC, USA). The primary analysis was estimation of the sensitivity and specificity of %CDT (cutoff point of 2.6%) for detecting past 30-day ''at-risk,'' ''heavy,'' and ''frequent heavy'' drinking. Ninety-five percent exact binomial confidence intervals were calculated for sensitivity and specificity. Receiver operating characteristic (ROC) curves, plots of sensitivity versus 1-specificity across the range of possible cut points for %CDT, were estimated to summarize the overall diagnostic accuracy of %CDT as well as to evaluate the optimal cut-off point for distinguishing subjects with ''at-risk,'' ''heavy,'' and ''frequent heavy'' levels of drinking. The point of perfect classification (i.e., 100% sensitivity and specificity) is in the upper left hand corner of the plot. We defined the optimal cut-off point as the single point on the curve that is closest to the top left corner of the graph (i.e., the point that maximizes the combination of sensitivity and specificity). The area under the ROC curve (AUC) is a summary measure of the performance of %CDT and represents the probability of ranking a randomly chosen ''at-risk'' drinker above a randomly chosen lesser than ''at-risk'' drinker. An AUC of 1.0 represents a perfect test and while a value of 0.5 represents a test that does not discriminate better than chance. Positive and negative predictive values (PPV, NPV, the probability of having [PPV] or not having [NPV] the condition given the test result) were estimated to further describe the markers.
Exploratory analyses, which stratified by gender and viral hepatitis (hepatitis B or C or both versus neither), were performed to assess potential differences in the accuracy of %CDT across subgroups. Secondary analyses were also conducted to evaluate the accuracy of %CDT for detecting past 14-day ''atrisk'' drinking and of the marker GGT as a test for detecting past 30-day ''at-risk,'' ''heavy,'' and ''frequent heavy'' drinking in an HIV-infected cohort.
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We also evaluated the performance of a test discussed in the literature which combines CDT and GGT: 0.8 )ln(GGT) '1.3 )ln(%CDT) 0g%CDT (Sillanaukee & Olsson, 2001) .
Results
Of the 400 subjects in the cohort, 394 met our study criteria, yielding 1123 available serum samples, of which we tested 300 from unique subjects. Table 1 provides characteristics of study subjects: 34% and 16% drank ''at-risk'' and ''heavy'' amounts, respectively; mean age was 44 years; 77% were men; and median CD4 count was 389. More than half were currently taking antiretroviral medication. More than half had viral hepatitis, mainly hepatitis C. Median GGT levels were above normal.
The estimated sensitivity of %CDT for detecting past 30-day ''at-risk,'' ''heavy,'' and ''frequent heavy'' drinking amounts was 28%, 36% and 41%, respectively (Table 2) . Corresponding estimates for specificity were 90%, 88% and 86%, respectively. In analyses that stratified by gender, estimates of sensitivity of %CDT appeared lower for women compared to men; however, the differences were not statistically significant; estimates of specificity were similar for the two groups ( Table 3 ). Sensitivity of %CDT was lower for the subjects with viral hepatitis compared to those without, although the difference was not statistically significant. Specificity did not appear to differ by viral hepatitis status.
The ROC curves for %CDT in detecting 30-day levels of unhealthy alcohol use in the overall sample appear in Figures 1Á3. The ROC curves show that with increasing amounts of drinking, %CDT has greater diagnostic accuracy, i.e., the estimated AUC for %CDT was 0.59, 0.60, and 0.68 for 30-day ''atrisk,'' ''heavy,'' and ''frequent heavy'' drinking, respectively. The optimal %CDT cut-off points for detecting past 30-day ''at-risk,'' ''heavy,'' and ''frequent heavy'' drinking were 2.2 (sensitivity 0 39%, specificity081%), 2.3 (sensitivity047%, specificity0 78%), and 2.0 (sensitivity 073%, specificity 0 62%), respectively.
Secondary analyses indicated that the sensitivity of %CDT (at the manufacturer's recommended cutoff point) for detecting past 14-day unhealthy drinking ranged from 21% to 39%, and specificity ranged from 86% to 94%. The sensitivity of GGT for detecting past 30-day unhealthy drinking ranged from 79% to 91% for detecting ''at-risk,'' ''heavy,'' and ''frequent heavy'' drinking amounts while the specificity ranged from 28% to 32%.
The positive and negative predictive values of %CDT were 60% and 70%, respectively, for detecting 30-day ''at-risk'' drinking and 58% and 74%, respectively, for detecting 14-day ''at-risk'' drinking. The positive and negative predictive values for detecting 30-day ''heavy'' drinking were 35% and 88%, respectively. The area under the ROC curve for the plot of g%CDT sensitivity versus 1-specificity was 0.62 for detecting ''at-risk'' drinking, 0.63 for ''heavy'' drinking, and 0.73 for ''frequent heavy'' drinking.
Discussion
Among HIV-infected adults with alcohol problems, %CDT had poor overall accuracy for detecting unhealthy drinking. At the manufacturer's recommended cut-off point, %CDT had good specificity; however, the sensitivity was too low for %CDT to be a clinically useful screening test. At the optimal cutoff for %CDT in this sample, the diagnostic accuracy of %CDT did not improve sufficiently to make it a clinically useful screening test.
Although the sensitivity of %CDT for detecting ''at-risk'' drinking appeared higher for men and those without hepatitis, 31% and 43%, respectively, it remained unacceptably low for these subgroups. However, even in a population such as the HIV-LIVE cohort, with a high prevalence of unhealthy alcohol use, the PPV was only 60%. NPV of 70% was similarly not very high, consistent with the low observed sensitivity.
The sensitivity and specificity for detecting past 14-day ''at-risk'' drinking was similar to the 30-day data, meaning that %CDT did not perform any better even when drinking was more recent. The high specificity of %CDT could make it useful in sequential testing, i.e., as a follow-up test to a positive finding on a highly sensitive questionnaire that screened for unhealthy alcohol use. Such an approach would require further study of both the precision and cost-effectiveness of sequential testing for determining unhealthy alcohol consumption by patients with HIV.
In spite of its recognized shortcomings, we analyzed the operating characteristics of GGT for detecting unhealthy drinking in an HIV-infected cohort because it is a test whose results are commonly available in clinical practice. The sensitivity of GGT was high in our study, much higher than what has been generally reported in the literature where GGT has been shown to have similar or even lower sensitivity than %CDT in samples of undetermined HIV status. It is common for GGT to be elevated in HIV-infected individuals. The high median GGT in heavy'' drinking: ]4 drinks in a day for women; ]5 drinks in a day for men on at least 7 days in past 30 days. c'' frequent'' heavy: at least seven consecutive days of drinking ''heavy'' amounts in past 30 days. heavy'' drinking: ]4 drinks in a day for women; ]5 drinks in a day for men on at least 7 days in past 30 days. c ''frequent heavy'' drinking: at least seven consecutive days of drinking ''heavy'' amounts. our sample, likely of multifactorial etiology, resulted in a very high sensitivity of GGT for detecting unhealthy alcohol use in our sample. This high sensitivity of GGT came at a cost of specificity. Specificity was too low for GGT to be useful as a screening test for unhealthy alcohol use. Also, we found that g %CDT does not provide a clinically significant advantage over %CDT alone in HIVinfected individuals.
The operating characteristics of %CDT for detecting the spectrum of unhealthy alcohol use by HIV-infected adults has not received adequate attention. Many studies with adults with undetermined HIV status have found %CDT to have greater sensitivity than observed in this study (Bortolotti, De Paoli, & Tagliaro, 2006) . These studies included subjects who were drinking more heavily and tested whether %CDT could detect these heavier amounts (Anttila, Jarvi, Latvala, & Niemela, 2004; Chrostek, Cylwik, Szmitkowski, & Korcz, 2006; Zierau et al., 2005) . When studies that evaluated %CDT for detecting daily heavy alcohol consumption are ex-cluded, as was done in a systematic review by Koch et al (2004) , the range of %CDT sensitivity for detecting lower levels of consumption is similar to our findings.
This study had its limitations. First, it included a small number of people with ''frequent heavy'' drinking. On the other hand, this may also be viewed as a strength since we studied an adequate number of people with the condition that is the target of greater importance for screening Á the spectrum of unhealthy alcohol use Á thereby avoiding the spectrum bias that limited a number of prior studies. Nevertheless the sample size limited the precision of our estimates, particularly in subgroup analyses (e.g., by gender and viral hepatitis). Second, we did not study subjects who had never had alcohol problems. However, we did include subjects with abstinence and those who consumed amounts of alcohol in a range from moderate to heavy use. Third, since we were studying a biomarker, one might question what the reference standard should be. The common biomarkers mentioned, GGT and MCV, lack specificity, and self report may be biased. We chose a widely agreed-upon and validated self-report research tool; our interviews were conducted with assurance of confidentiality and coincide with both an alcohol breath test and blood testing to encourage truth telling.
This study had a number of strengths. We did not exclude people who used ART medications, had liver disease and other co-morbidities. As such, our sample provided a generalizable test of %CDT in HIVinfected adults. In addition, our sample was relatively young, CD4 counts were relatively high, HIV RNA viral loads were relatively low, and so the performances of %CDT and GGT in our study are not likely attributable to very advanced HIV disease.
These findings suggest that %CDT is not sufficiently sensitive for use in screening for unhealthy AIDS Care 1489 alcohol use by people with HIV infection. Next steps for research might include testing other biomarkers for this purpose. Numerous self-report questionnaires have been validated for detecting unhealthy alcohol use. These will likely remain the least expensive, most accurate and most easily implementable tools for screening patients with HIV for unhealthy alcohol use.
